Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors
Cambridge, U.K., [29 April 2021] – Cycle is proud to announce that Dr Alejandra Bruna has joined Cycle’s Board of Directors as Non Executive Director.
Dr Bruna is a cancer biologist who leads the Preclinical Modelling of Paediatric Cancer Evolution team at the Institute of Cancer Research, London. The Cycle team looks forward to working with Dr Bruna on all aspects of our business, and in particular on the developing pipeline at Varsity Pharmaceuticals, our new cancer research subsidiary announced in September 2020.
Alejandra Bruna – Non Executive Director – Cycle Group Holdings
Dr Bruna’s research team at the Institute of Cancer Research focuses on the use of refined preclinical models of aggressive solid paediatric tumours (pPDXs) in translational research. In particular, Dr Bruna aims to understand cancer’s adaptability responses and how these influence the choice of therapy. Dr Bruna uses simulations of complex clinically relevant models to help refine, improve, adapt and redesign current therapeutic strategies for long-term benefits. Dr Bruna obtained her Ph.D. from the University of Barcelona, followed by two postdoctoral fellowships at Mount Sinai School of Medicine, New York City and Vall d’Hebron Institute, Barcelona. Dr Bruna developed, coordinated and co-led a translational research framework for patient-derived tumour xenografts (PDXs) and short-term cultures of PDX cells with Professor Carlos Caldas at the Cancer Research UK Cambridge Institute.
GL-0064 (April 2021)